Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 7Specimen Handling 6Oxaliplatin 5Irinotecan 5S 1 (combination) 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4Capecitabine 4Biopsy 4Bevacizumab 4Radiotherapy 3Nivolumab 3Immunotherapy 3Drug Therapy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2titanium silicide 2spartalizumab 2lenvatinib 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Radiosurgery 2Photochemotherapy 2Interleukin-2 2Endoscopic Mucosal Resection 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × CA-4948 × Gastrointestinal × Clear all
NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡